Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1

Background Neutralization of interferon (IFN)-γ abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II but can be induced to do so by IFN-γ. Inducible tumor-specific...

Descripció completa

Dades bibliogràfiques

Autors principals:	David Cunningham, Paul Ross, Ruth Plummer, Joshua Savage, Gary Middleton, Mark Saunders, Daniel Palmer, Anne Thomas, Lucinda Billingham, Sally Clive, Vicky Coyle, John Bridgewater, Phillipe Taniere, Charlotte Gaskell
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2025-12-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/13/12/e012749.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!